Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141 [abstract] - Ferris, RL; Blumenschein, GR; Fayette, J; Guigay, J; Colevas, AD; Licitra, LF
J Clin Oncol. 2016;34 (Suppl): abstr 6009